Background Ventilator‐associated pneumonia (VAP) is a significant cause of morbidity and
mortality, complicating the medical course of approximately 10% of mechanically‐ventilated …

Background The increasing prevalence of ventilator-associated pneumonia (VAP) due to
either multidrug-resistant (MDR) organisms or infections with limited treatment options (ie …

Introduction The efficacy and safety of adjunctive inhaled antibiotic therapy for ventilator-
associated pneumonia (VAP) was systematically reviewed based on updated studies …

Background For ventilator-associated pneumonia (VAP), the safety of short-course versus
long-course antibiotic therapy is still debated, especially regarding documented VAP due to …

Background Ventilator-associated pneumonia (VAP) is associated with increased mortality,
prolonged hospitalisation, excessive antibiotic use and, consequently, increased …

Ventilator‐associated pneumonia (VAP) is the most common infectious complication in
patients receiving mechanical ventilation and accounts for exorbitant use of resources in the …

Introduction: Ventilator-associated pneumonia (VAP) is a distinct clinical entity characterized
by an onset after 48 hours of the application of mechanical ventilation (MV). Protocols exist …

Background We performed a systematic review and meta-analysis of short-vs long-duration
antibiotic regimens for ventilator-associated pneumonia (VAP). Methods We searched …

Ventilator-associated pneumonia (VAP) is the most common infectious complication in the
intensive care unit. It can increase duration of mechanical ventilation, length of stay, costs …

Ventilator-associated pneumonia (VAP) is the most frequent life-threatening nosocomial
infection in intensive care units. The diagnostic is difficult because radiological and clinical …